Insights
/
Blog
/
SubQperior: An Innovative and Superior Syngeneic Model System

SubQperior: An Innovative and Superior Syngeneic Model System

SubQperior syngeneic tumor models developed by Reaction Biology overcome subcutaneous tumor implantation challenges through improved techniques that deliver homogenous tumor growth and superior statistical value without ulceration issues. These models advance immune-oncology drug development by enabling more reliable efficacy studies for immunotherapy programs targeting cancer immunotherapy development.

Scientist.com

Published on

February 18, 2021

Date: March 18. Time: 10:30 AM EST.

The novel SubQperior tumor models overcome common challenges of subcutaneous tumor models based on improved tumor cell implantation technique. SubQperior efficacy studies provide outstanding statistical value due to homogenous tumor growth and absence of ulceration issues. In this webinar, we present how SubQperior syngeneic models are used at Reaction Biology to advance immune-oncology drug development programs to create efficacious immunotherapies. All oncology program leaders are welcome to take part in the webinar.

Abstract molecular cluster with three connected blue-green spheres on a white background.

Take the Next Step

Explore Suppliers

Browse trusted partners with relevant expertise

Review Capabilities

Compare services, experience, and past work

Start Your Project

Connect and begin collaborating

Browse Suppliers

Post a Project

How It Works

Written by

Scientist.com

Share this post

TOPICS

Pharmacology

Disease Models

Subscribe to our newsletter

Subscribe to receive the latest news and innovations straight to your inbox.

Your subscription could not be saved. Please try again.

Your subscription has been successful.

Topics of Interest

Biology
Biometrics
Chemical & Compound Analysis
Chemistry, Manufacturing & Controls
Clinical Trials
Discovery Chemistry
DMPK
Health Economics & Outcomes Research (HEOR)
Human Biological Samples (HBS)
Market Access
Non-Human Biological Samples (NHBS)
Pharmacology
Raw Materials
Real-World Data (RWD)
Real-World Evidence (RWE)
Safety & Pharmacovigilance
Toxicology
Medical Communications

Email address

I would like to receive the monthly Scientist.com newsletter.

I agree to receive email communication from Scientist.com and accept the data privacy statement.

By submitting your information, you agree to our Terms of Service and Privacy Policy. You can opt out anytime.

Subscribe to our newsletter

Subscribe to receive the latest news and innovations straight to your inbox.

Your subscription could not be saved. Please try again.

Your subscription has been successful.

Topics of Interest

Biology
Biometrics
Chemical & Compound Analysis
Chemistry, Manufacturing & Controls
Clinical Trials
Discovery Chemistry
DMPK
Health Economics & Outcomes Research (HEOR)
Human Biological Samples (HBS)
Market Access
Non-Human Biological Samples (NHBS)
Pharmacology
Raw Materials
Real-World Data (RWD)
Real-World Evidence (RWE)
Safety & Pharmacovigilance
Toxicology
Medical Communications

Email address

I would like to receive the monthly Scientist.com newsletter.

I agree to receive email communication from Scientist.com and accept the data privacy statement.

By submitting your information, you agree to our Terms of Service and Privacy Policy. You can opt out anytime.

Read Further

Blog

What Experimental Data Do AI-Designed Antibodies Need?

Innovation Hub

SubQperior: An Innovative and Superior Syngeneic Model System

Take the Next Step

Explore Suppliers

Review Capabilities

Start Your Project

Subscribe to our newsletter

Subscribe to our newsletter

Read Further

What Experimental Data Do AI-Designed Antibodies Need?

From Vague Claims to Strict Compliance: The Global Regulatory Crackdown on Greenwashing

The Evolving Landscape of Drug Discovery for Metabolic Diseases

Regulatory Evolution in Substantial Evidence: The FDA’s One-Trial Pathway and the Strategic Implications for Biopharmaceutical Development

June 2026 Medical/Commercial Pulse Check

Accelerating the Design–Build–Test–Learn Cycle for AI-Driven Antibody Discovery

Screening the Unscreenable: How Physics-Grounded AI Is Expanding the Reach of Drug Discovery

Reducing risk in CRO studies: Choosing the right cell models for outsourced research

Cutting Months Off AAV Programs: The Synthetic DNA Shift

Speed Matters: Why RWE Acceleration Starts Upstream with Reusable Data

Industry Insights: Behind the Scenes of BPS Bioscience Custom R&D

Making Sustainability More "Sustainable": Driving Transformation at Scale within Biopharma

Comprehensive Plasma cell-free RNA Profiling for Superior Cancer Detection

Advanced Screening Strategies for Molecular Glue Discovery

Why Large CROs and CDMOs Should Embrace Research Orchestration Platforms - Even with Existing Pharma Clients

AI in HEOR: Three Ways Artificial Intelligence Is Accelerating Evidence Generation

Supplier Spotlight: RadMD Imaging

AI Is Expanding What's Possible in Drug Discovery. Operational Friction Still Determines How Fast It Happens.

The Science of the "Gut Feeling": Why Techs are a Lab's Best Diagnostic Tool

Supplier Spotlight: MedChemExpress

HealthEconomics.com 2026 Pulse Check – March

Cell Line-Derived Xenografts: A Reliable Platform for Preclinical Cancer Drug Testing

2026 PharmDev Roadmap: The Regulatory Shift

Five Reasons Leading CNS Programs Rely on BrainXell for Custom iPSC Models

From the Colony to the Roadmap: The FDA's New Stance on NAMs and Why it Matters

2026 PharmDev Roadmap: The Strategic Partner

2026 PharmDev Roadmap: The Predictive Model

2026 PharmDev Roadmap: The Complexity Spike

Explore FUJIFILM's Cyclic Peptide Discovery Service

2026 PharmDev Roadmap: The Resilience Pivot

Read Further

Epitope Mapping Using MAbTope: MAbSilico's AI Tool

The Potential Impact of IVDR on Diagnostic Testing Across the EU

Benchmarking Survey: Can we reduce procurement time in HEOR & RWE?

Top 5 Signs You Are Ready for an Online Master's Degree in 21st Century Healthcare

The Digital Backbone for Modern Life Sciences